Ethris, a Munich, Germany-based biotechnology company advancing next-generation RNA therapeutics and vaccines, raised $5M in funding.
The Bill & Melinda Gates Foundation provided the funding.
The company intends to use the funds to rapidly reach Phase 2 readiness and build out the CMC manufacturing process for the next clinical trial.
Led by CEO Dr. Carsten Rudolph, Ethris is a clinical stage biotech company which is using its proprietary RNA and lipidoid nanoparticle technology platform to discover, design and develop innovative therapies. It specializes in delivering stabilized mRNAs directly to the respiratory system via optimised formulation and nebulisation technologies. The company is advancing its mRNA pipeline of immuno-modulation, protein replacement therapies, and differentiated vaccines, aiming to improving patients’ lives.
ETH47 is Ethris’ first-in-class inhaled mRNA-based candidate with the potential to address a broad spectrum of chronic respiratory diseases and emerging respiratory infections and is currently being evaluated in a Phase 1 clinical trial.
Commenting on the news, Carsten Rudolph said: “Ethris’ lead mRNA-based product candidate ETH47 was designed to have broad antiviral capabilities, placing it in a distinct position to address a range of virus-induced respiratory infections and chronic respiratory diseases. Ethris, supported by the new funding from the Gates Foundation, will accelerate its clinical development, initially targeting asthma exacerbations, an indication with a high unmet medical need where approximately 80% of acute asthma attacks are associated with virus infections. We are grateful for the foundation’s support in our mission to combat the global burden of current and emerging respiratory infections by harnessing the full scope of ETH47’s virus-agnostic potential.”
FinSMEs
18/06/2024